Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.85
-0.16-2.00%
At close: -
$8.09
0.243.06%
After Hours: 7:16 PM EDT
Comments
Loading...
Rocket Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RCKT | Benzinga
Rocket Pharmaceuticals Inc has a consensus price target of $45.2 based on the ratings of 20 analysts. The high is $75 issued by Evercore ISI Group on September 30, 2022. The low is $15 issued by Goldman Sachs on March 3, 2025. The 3 most-recent analyst ratings were released by Needham, BMO Capital, and Scotiabank on April 9, 2025, March 12, 2025, and March 3, 2025, respectively. With an average price target of $48 between Needham, BMO Capital, and Scotiabank, there's an implied 493.33% upside for Rocket Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
BMO Capital
Scotiabank
Goldman Sachs
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Rocket Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 419.16% | Needham | Gil Blum51% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 518.05% | BMO Capital | Kostas Biliouris33% | → $50 | Initiates | → Outperform | Get Alert |
| 03/03/2025 | Buy Now | 542.77% | Scotiabank | Greg Harrison49% | $51 → $52 | Maintains | Sector Outperform | Get Alert |
| 03/03/2025 | Buy Now | 85.41% | Goldman Sachs | Richard Law44% | $29 → $15 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 344.99% | Canaccord Genuity | Whitney Ijem54% | $39 → $36 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 567.49% | Chardan Capital | Geulah Livshits46% | $62 → $54 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 419.16% | Needham | Gil Blum51% | $52 → $42 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | 258.47% | Jefferies | Andrew Tsai26% | → $29 | Initiates | → Buy | Get Alert |
| 11/19/2024 | Buy Now | 382.08% | Canaccord Genuity | Whitney Ijem54% | $39 → $39 | Maintains | Buy | Get Alert |
| 11/19/2024 | Buy Now | 443.88% | Leerink Partners | Mani Foroohar49% | $46 → $44 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 703.46% | Cantor Fitzgerald | Josh Schimmer56% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/19/2024 | Buy Now | 542.77% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 666.38% | Chardan Capital | Geulah Livshits46% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | 666.38% | Chardan Capital | Geulah Livshits46% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 542.77% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 518.05% | Scotiabank | Greg Harrison49% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 09/30/2024 | Buy Now | 369.72% | Canaccord Genuity | Whitney Ijem54% | $38 → $38 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 542.77% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 567.49% | JP Morgan | Eric Joseph44% | $50 → $54 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 703.46% | Cantor Fitzgerald | Josh Schimmer56% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/06/2024 | Buy Now | 666.38% | Chardan Capital | Geulah Livshits46% | $62 → $62 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 542.77% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 394.44% | Canaccord Genuity | Whitney Ijem54% | $49 → $40 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 666.38% | Chardan Capital | Geulah Livshits46% | $62 → $62 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 542.77% | Needham | Gil Blum51% | $53 → $52 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 555.13% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 555.13% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 382.08% | Goldman Sachs | Richard Law44% | → $39 | Initiates | → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 567.49% | UBS | Colin Bristow40% | $56 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 518.05% | JP Morgan | Eric Joseph44% | $55 → $50 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 703.46% | Cantor Fitzgerald | Josh Schimmer56% | $65 → $65 | Maintains | Overweight | Get Alert |
| 02/13/2024 | Buy Now | 555.13% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | 703.46% | Cantor Fitzgerald | Louise Chen55% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 555.13% | Needham | Gil Blum51% | → $53 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 703.46% | Cantor Fitzgerald | Josh Schimmer56% | → $65 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 493.33% | Stifel | Dae Gon Ha48% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 555.13% | Needham | Gil Blum51% | $60 → $53 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 480.96% | Canaccord Genuity | Whitney Ijem54% | $49 → $47 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 654.02% | Chardan Capital | Geulah Livshits46% | → $61 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 641.66% | Needham | Gil Blum51% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 493.33% | Stifel | Dae Gon Ha48% | $53 → $48 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 641.66% | Needham | Gil Blum51% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | Buy Now | 654.02% | Chardan Capital | Geulah Livshits46% | $63 → $61 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 332.63% | Raymond James | Steven Seedhouse60% | $33 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 641.66% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 641.66% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 678.74% | Chardan Capital | Geulah Livshits46% | $65 → $63 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 641.66% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | 456.24% | Morgan Stanley | Michael Ulz63% | → $45 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 505.69% | SVB Leerink | Mani Foroohar49% | $50 → $49 | Maintains | Outperform | Get Alert |
| 12/23/2022 | Buy Now | 332.63% | B of A Securities | Greg Harrison49% | $38 → $35 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | 518.05% | SVB Leerink | Mani Foroohar49% | $54 → $50 | Maintains | Outperform | Get Alert |
| 12/06/2022 | Buy Now | 567.49% | SVB Leerink | Mani Foroohar49% | $56 → $54 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 555.13% | Canaccord Genuity | Whitney Ijem54% | → $53 | Initiates | → Buy | Get Alert |
| 11/07/2022 | Buy Now | 307.91% | Raymond James | Steven Seedhouse60% | $34 → $33 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 641.66% | Needham | Gil Blum51% | $62 → $60 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 332.63% | BTIG | Yun Zhong36% | → $35 | Initiates | → Buy | Get Alert |
| 10/03/2022 | Buy Now | 703.46% | Chardan Capital | Geulah Livshits46% | $62 → $65 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 320.27% | Raymond James | Steven Seedhouse60% | $24 → $34 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 641.66% | SVB Leerink | Mani Foroohar49% | $65 → $60 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 827.07% | Evercore ISI Group | Joshua Schimmer44% | $65 → $75 | Maintains | Outperform | Get Alert |
| 09/27/2022 | Buy Now | 666.38% | UBS | Colin Bristow40% | $68 → $62 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 196.66% | Raymond James | Steven Seedhouse60% | $22 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 592.21% | Stifel | Dae Gon Ha48% | $67 → $56 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | 171.94% | Raymond James | Timur Ivannikov30% | → $22 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | Buy Now | 691.1% | SVB Leerink | Mani Foroohar49% | $66 → $64 | Maintains | Outperform | Get Alert |
| 05/20/2022 | Buy Now | 666.38% | Chardan Capital | Geulah Livshits46% | $60 → $62 | Maintains | Buy | Get Alert |
| 05/20/2022 | Buy Now | 715.82% | SVB Leerink | Mani Foroohar49% | $64 → $66 | Maintains | Outperform | Get Alert |
| 05/17/2022 | Buy Now | 666.38% | Needham | Gil Blum51% | $75 → $62 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT) stock?
The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Needham on April 9, 2025. The analyst firm set a price target for $42.00 expecting RCKT to rise to within 12 months (a possible 419.16% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Needham, and Rocket Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
There is no last upgrade for Rocket Pharmaceuticals
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
There is no last downgrade for Rocket Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a reiterated with a price target of $42.00 to $42.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $8.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
